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function and pathology (former unchanged, latter markedly improved)Macrophage and myofibroblast involvement in ischemic acute renal
may be due to the time frame of this experiment, and longer outcomefailure is attenuated by endothelin receptor antagonists.
measures need to be assessed.Background. Endothelin (ET) may be a mediator of injury following
ischemia-induced acute renal failure (ARF). ET receptor (ETR) antag-
onists have been reported to increase survival rates and lower serum
creatinines when administered postrenal ischemia-reperfusion injury
Endothelin (ET) has proven to be the most potentin the rat. Renal cellular and extracellular matrix responses to this
therapy have not been addressed. vasoconstrictor known to humans [1]. ET is a 21-amino
Methods. We investigated the use of ETR antagonists, PD 156707 acid peptide in which the actions are mediated by binding(ETA) and SB 209670 (ETA and ETB) in the treatment of sublethal
to three surface receptors ETA, ETB1, and ETB2 [2, 3].postischemic ARF. The right kidney of female Sprague-Dawley rats
weighing approximately 200 g was removed. After five days, the left Autoradiography has revealed that ETA receptors are
renal pedicle was occluded for 45 minutes. Twenty-four hours after mainly localized to blood vessels throughout the kidney,renal ischemia, one of two ETR antagonists, PD 156707 (N 5 7) or
particularly arcuate arteries and veins at the corticomed-SB 209670 (N 5 8), was administered. Experimental animals were
compared with an ischemic group receiving only saline (N 5 9). Three ullary junction. ETB receptors are concentrated in the
nephrectomized groups that did not undergo ischemia but that received medulla on nonvascular structures such as tubules andinfusions of saline (N 5 6), PD 156707 (N 5 6), and SB 209670 (N 5
collecting ducts [4, 5].6), respectively, were also studied. Animals were sacrificed one week
postischemia. Quantitation of monocytes and macrophages (Mo/Mφ), ET has been implicated in the pathogenesis of ische-
a-smooth muscle actin–positive myofibroblasts, and collagens type III mic acute renal failure (IARF). Elevated levels of ET-1and IV was performed by immunohistochemical staining. Cell kinetics
in kidney tissue [6] and plasma [7] have both been re-were examined by staining for apoptosis with terminal deoxyuridine
triphosphate (dUTP) nick end labeling and for proliferation with prolif- ported in patients with IARF. Recently, results have
erating cell nuclear antigen.
indicated that infusion of ET-1 antibody in the rat hasResults. All ischemic groups of rats initially developed raised serum
creatinine levels; however, no significant difference was observed be- provided limited protection before induction of IARF
tween the groups (Kruskal–Wallis). Creatinines returned to preis- [6, 8, 9]. Conversely, infusion of ET receptor (ETR) an-chemic values in all groups by the time of sacrifice. No significant
tagonists may attenuate IARF when administered postis-difference in kidney weights or body weights was found between
groups. Histologically, infiltration of Mo/Mφ was significantly reduced chemia [10–13]. Although renal hemodynamics have
in groups treated with ETR antagonists (P , 0.001). The presence of been extensively explored in these models, changes in
myofibroblasts was also significantly reduced in the antagonist-treated
renal histology have been largely ignored.groups (P , 0.001). This was also paralleled by reduced quantities of
collagen IV in the treated rat groups (P , 0.001). The interstitial area The studies of Gellai et al in the kidney showed that
was also significantly greater in the saline group (P , 0.001). The ETR antagonists reduced mortality through improve-amount of collagen III did not significantly differ between rat groups.
ments in sodium resorption and potassium excretion [11,Apoptosis was reduced (P , 0.001) by treatment with ETR antagonists,
whereas proliferation was enhanced (P , 0.005). All non-ischemic 12]. They implied but did not prove that the duration
groups showed no variation in any parameter studied at this time point. of renal injury was diminished through the use of ETRConclusions. Treatment of ischemic ARF in the rat with ETR antago-
antagonists. Death in IARF is usually due to metabolicnists PD 156707 and SB 209670 attenuated cellular infiltration and
matrix accumulation. An advantage of one antagonist over the other complications (mainly hyperkalemia), which in the hu-
could not be determined in this study. The marked discrepancy between man situation, is controlled by renal replacement therapy
(for example, dialysis). Thus, a more important effect of
the ETR antagonists may be the potential for lesseningKey words: fibroblasts, ischemic renal disease, ARF, extracellular ma-
trix, vasoconstriction, endothelin. of duration, rather than severity, of renal failure.
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nephrosis [14], ureteric obstruction [15], cyclosporine earlier here, and these control groups were named SC
(saline–no treatment), SBC (SB 209670), and PDC (PDnephrotoxicity [16, 17], and pyelonephritis [18]. These
cells contribute to the production of extracellular matrix. 156707). Serum creatinine was monitored each day to
the time of sacrifice one-week postischemia. The kidneyAccumulation of extracellular matrix in the tubulointer-
stitium is the best predictive indicator of the outcome was removed, decapsulated, and weighed immediately.
Tissue was taken for histology and immunohistochemistry.of renal disease [19].
Evidence is accumulating in the literature that ET-1 All procedures were performed in accordance with
the Animal Ethics Committee of the Royal Children’shas profibrotic effects. Benign et al [20] showed increased
long-term survival of rats after treatment with bosentan, Hospital Research Institute.
a nonselective ETR antagonist, in the remnant kidney
Histologymodel. These animals also had marked improvements
in systolic blood pressure, proteinuria, and serum creati- Hematoxylin and eosin. Formalin-fixed paraffin sec-
tions 2 mm thick were dewaxed and brought to waternine. ET has also been implicated in the production of
extracellular matrix components in murine lupus nephri- through graded alcohols. Sections were then stained for
five minutes in Harris hematoxylin and were washedtis. Nakamura et al demonstrated that a specific ETA
receptor antagonist ameliorated lupus nephritis and in- in Scott’s tap water for 10 seconds. Staining was then
continued by immersion in eosin Y for five minutes.creased the expression of mRNA for matrix components,
matrix metalloproteinases, and the tissue inhibitor of Sections were then dehydrated through graded ethanols,
cleared in xylene, and mounted in dePex (BDH Chemi-metalloproteinases [21]. In addition, further evidence is
provided by mice transgenic for ET-1. These animals cals, Poole, UK).
Combined silver methamine/Masson trichrome. For-develop significant tubular damage and interstitial fibro-
sis [22]. Interestingly, this is also observed in ET-2 malin-fixed paraffin sections 2 mm thick were dewaxed
and brought to water through graded alcohols. Sectionstransgenic mice [23].
The aim of these studies was to determine the effect of were treated with 0.5% periodic acid for 30 minutes,
washed, and then stained in silver methamine solutionETR antagonists on the composition of cellular infiltrates
and renal extracellular matrix in sublethal ischemic ARF. at 50 to 608C until sections turned brown (approximately
60 min). Staining was then checked microscopically untilThe functional benefits of treatment of ischemic ARF
were also addressed. sufficient impregnation was achieved. Fixation was per-
formed in 5% sodium thiosulfate for 20 seconds, and
then sections were placed into Harris hematoxylin for
METHODS
five minutes. Sections were dipped into Scott’s tap water
Experimental model and were then stained in Masson red for five minutes.
Without rinsing, the sections were then placed into 1%A right unilateral nephrectomy was performed through
a flank incision in female Sprague-Dawley rats of approx- aqueous phosphotungstic acid for five minutes. Counter-
staining was performed in 1% aqueous light green forimately 200 g body weight under 4% fluothane in oxygen.
Five days later, an ischemic injury was induced by occlu- five minutes, and then sections were quickly dehydrated
through graded alcohols, cleared in xylene, and mountedsion of the left renal pedicle with arterial clamps for 45
minutes using intraperitoneal ketamine/xylazine (9 mg/ in dePex. Quantitation of tubulointerstitium was per-
formed on these sections.kg:1 mg/kg) anesthesia.
The experimental model was similar to that employed
Immunohistochemistryby Gellai et al, except that the extracellular fluid volume
of the animals was maintained by daily administration A modification of the avidin-biotin-peroxidase com-
plex (ABC) immunoglobulin enzyme bridge techniqueof intraperitoneal saline to rats with a loss of more than
5 g of body weight from the previous day [11, 12]. The [24] was used for immunohistochemistry. Sections 2 mm
thick obtained from formalin-fixed, paraffin-embeddedvolume administered did not exceed 5 ml each day.
The effects of a three-hour infusion, 24-hour postische- tissue were dewaxed and brought to water through
graded alcohols. Following digestion of tissue, endoge-mia of PD 156707 (PDI group, N 5 7; Pfizer Pharmaceu-
ticals Pty Ltd., London, UK) 5 mg/kg bolus, then 1 mg/ nous peroxidase activity was eliminated by treatment
with methanol containing 0.03% hydrogen peroxide forkg/hr and SB 209670 (SBI group, N 5 8; Pfizer) 5 mg/
kg bolus then 1 mg/kg/min were compared with a group 20 minutes.
Sections were then incubated with normal serum forreceiving only saline (SI group, N 5 9). A corresponding
control group for each of these groups of animals was 20 minutes to block nonspecific antibody binding sites
before incubation with primary antibody for one hour.performed (N 5 6). Each of these three groups received
a unilateral nephrectomy but no occlusion of the renal Primary antibodies used were collagen IV and III
(Southern Biotechnology Associates Inc., Birmingham,pedicle. Infusions were performed exactly as specified
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AL, USA), a-smooth muscle actin (a-SMA; DAKO point counting was undertaken at 31000 (oil immersion),
in which a total of 20 graticule fields were counted (ap-Corp., Carpinteria, CA, USA), ED-1 for Mo/Mφ (Sero-
tec Ltd., Oxford, UK), sheep anti-clusterin [25], vimentin proximately 1000 nuclei per slide 2 0.61 mm2 total area/
slide). The percentage of fractional area was calculated(Dako), and proliferating cell nuclear antigen (PCNA;
Dako). Tissue sections were then stained consecutively as shown here [18]:
with biotinylated IgG for 10 minutes and avidin-biotin
Percentage of fractional area 5
horseradish peroxidase complex for 15 minutes (Vecta-
number of grid intersections with positive staining/
stain ABC ELITE kit; Vector Laboratories Inc., Burl-
total number of grid intersections 3 100
ingame, CA, USA). Peroxidase activity was demon-
strated by staining with a freshly prepared substrate This corresponds to the percentage of positive area in
the total area counted of the section.solution of 3,39-diaminobenzidine tetrahydrochloride
(Dako) in 0.1 m phosphate-buffered saline containing
Statistical analysis0.03% hydrogen peroxide. Sections were counterstained
in Harris’ hematoxylin and mounted in dePex. Statistical analysis was performed between experimen-
tal groups by applying Kruskal–Wallis nonparametric
Terminal deoxytransferase uridine triphosphate nick testing, with correction for multiple comparisons. Sig-
end labeling (TUNEL) nificance was accepted for a P value of less than 0.05.
Data are expressed as mean 6 standard errors of theCells undergoing apoptosis were identified by 39 in
situ end labeling of fragmented DNA with biotinylated mean (sem) or mean 6 standard deviation, as appro-
priate; the error bars on all graphs are sem. Mann–deoxyuridine-triphosphate [26, 27]. DNA fragmentation
is the hallmark of cells in which endonucleases have been Whitney nonparametric testing was used to characterize
differences between groups in Table 1.activated during the process of cell death [28]. Terminal
transferase labels the nicked DNA 39 with labeled deoxy-
uridine triphosphate (dUTP), which is subsequently de-
RESULTS
tected by immunohistochemical techniques.
Weight measuresSections of formalin-fixed tissue were dewaxed and
hydrated. Following digestion with proteinase K (2 mg/ At the time of renal artery occlusion, there was no
significant difference between body weights of the ani-ml; Sigma, St. Louis, MO, USA), sections were consecu-
tively washed in terminal deoxynucleotidyl transferase mals (Table 1). A tendency to lose body weight in the
week following the occlusion was observed, but there(TdT) buffer (0.5 m cacodylate, pH 6.8, 1 mm cobalt
chloride, 0.15 m NaCl) and were then incubated at 378C was no significant difference between the ischemic SI,
SBI, and PDI rat groups. Body weights in the three non-with TdT (25 U; Boehringer-Mannheim, Mannheim,
Germany) and biotinylated dUTP (1 nmol/ml). After ischemic groups (SC, SBC, and PDC) remained constant
throughout the study. At sacrifice, all kidneys that hadwashing in TB buffer (300 mm NaCl, 30 mm sodium
citrate) to terminate the reaction, incorporation of bio- been ischemic were heavier than contralateral kidneys
weighed prior to the ischemic insult and had a smoothtinylated dUTP was detected by a modification of the
ABC method [24]. Horseradish peroxidase conjugated capsule (P , 0.005; Table 1). The three control groups
that received a nephrectomy and infusion showed onlystrepavidin-biotin complex was applied (Vector). The
sections were then developed with 3,39-diaminobenzi- a minor increase in kidney weight when compared with
the contralateral kidney (P , 0.05; Table 1).dine tetrahydrochloride and counterstained in Harris he-
matoxylin. A mouse spleen with apoptosis of antibody-
Functional dataforming cells was used as a positive control for TUNEL.
The omission of TdT during dUTP nick end labeling Serum creatinine levels after unilateral nephrectomy
and prior to ischemia were not significantly differentprovided a negative control.
between groups. At 24 hours postischemia, all rats in
Point counting the ischemic groups had ARF, with creatinines in excess
of 0.15 mmol/liter. As shown in Figure 1A, the serumPoint counting was performed in the renal cortex and
corticomedullary junction for each animal following rou- creatinines steadily decreased toward normal, with no
differences observed between groups at any time. Thetine established methods [18, 29]. One hundred points
were counted on a 1 cm2 eyepiece graticule with 10 equi- three non-ischemic control groups maintained constant
serum creatinine values throughout the study (Fig. 1B).distant grid lines. A total of 12 high power fields (3400)
per section was counted for each animal in all groups
Histologic changes(eight cortical and four corticomedullary fields). Each
high power field was 0.076 mm2, with 0.91 mm2 being All three non-ischemic control groups (SC, SBC, and
PDC) had minimal changes in the kidney. There wasthe total area counted per slide. TUNEL and PCNA
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Table 1. Body and kidney weights of all groups
Days after occlusion
Pre-ischemia Day 1 Day 2 Day 3 Day 4 Day 7
Body weight g
SI group 208 6 10.1 204 6 8.9 197 6 11.2 196 6 10.2 194 6 10.4 207 6 8.6
SBI group 207 6 10.2 206 6 10.3 200 6 8.9 194 6 11.8 192 6 8.8 198 6 8.2
PDI group 209 6 11.0 206 6 11.7 192 6 8.5 194 6 9.7 193 6 8.8 205 6 11.0
SC group 203 6 9.05 208 6 15.4
SBC group 209 6 17.1 208 6 10.5
PDC group 215 6 7.4 216 6 6.34
Kidney weight g Contralateral
SI group 0.79 6 0.06a 1.47 6 0.2ab
SBI group 0.79 6 0.05a 1.56 6 0.4ab
PDI group 0.80 6 0.06a 1.42 6 0.2ab
SC group 0.78 6 0.05a 0.95 6 0.1ab
SBC group 0.79 6 0.08a 1.04 6 0.1ab
PDC group 0.80 6 0.04a 1.15 6 0.1ab
Abbreviations are in the Appendix.
a P , 0.005 between contralateral kidney weights and corresponding day 7 kidneys
b P , 0.05 between control groups SC, SBC and PDC as compared to corresponding ischemic groups, i.e. SI vs. SC group, etc.
some edema and an occasional cystic tubule. There ap- Myofibroblast localization
peared to be no thickening of basement membranes or The SI ischemic group had increased levels of staining
Bowman’s capsule. for a-SMA–positive cells in the interstitium. These cells
One week following the ischemic insult, the appear- formed a network around tubules throughout the cortex
ance of the postischemic kidney was similar to that pre- and medulla (Fig. 3A). There was significantly less stain-
viously described by Finn and Chevalier [30] and Bohle ing in the kidney for those rats treated with ETR antago-
et al [31]. Although a small percentage of tubular lumens nists (P , 0.001; Fig. 5). Within the ETR antagonist
were narrow with swollen epithelium, most were dilated groups, staining was confined to vessels and areas around
with flattened tubular epithelial cells. Intratubular casts tubules that appeared damaged (Fig. 3 B, C). Nonische-
were scattered throughout the renal cortex, with large mic control groups showed minimal staining for a-SMA
amounts present in the papilla and inner medulla. This when compared with their ischemic equivalents (P ,
was especially evident in the SBI group. Tubules were 0.001; Fig. 5).
widely separated by the presence of cellular infiltrate,
Monocyte/macrophage localizationedema, and matrix expansion in the interstitium. Intersti-
tial expansion was minimal in nonischemic groups, with Cells demonstrating ED-1 staining for Mo/Mφ were
differences observed between these and ischemic groups present throughout the renal interstitium of SI ischemic
being highly significant (P , 0.001; Fig. 2). This expan- rats and were most prominent at the corticomedullary
sion was not as marked in the ischemic groups treated junction (Fig. 3D). Ischemic groups treated with PD
with ETR antagonists when compared with the untreated 156707 or SB 209670 showed a marked decrease in stain-
SI group (P , 0.001; Fig. 2). Areas of thickened tubular ing (P , 0.001) as compared with the SI group (Fig. 3 E,
basement membranes were evident with silver/Masson F, and Fig. 4). Nonischemic control groups had minimal
trichrome staining. These tended to correspond to the staining of ED-1–positive cells when compared with is-
worst areas of matrix expansion. Many tubular epithelial chemic equivalents (P , 0.001; Fig. 4).
cells contained silver dense granules in their cytoplasm.
Vimentin and clusterinCongestion of the vasculature with erythrocytes at the
corticomedullary junction was prominent in all ischemic Vimentin expression did not appear to be altered be-
groups. Patchy areas of cortical tubular necrosis were tween the ischemic groups. Expression was localized to
evident, with swelling and loss of attachment of tubular the mesangial cells of the glomerulus and large blood
epithelial cells to the basement membrane being exten- vessels. There was faint staining around some damaged
sive, especially in the SI group. Sloughing of cells into tubules in the saline ischemic group.
the tubular lumens was also evident. Glomeruli appeared Clusterin was highly expressed by tubules with dam-
relatively normal with a widened Bowman’s space in all aged epithelium. There appeared to be no differences
groups. The SI group showed expansion of the Bowman’s observed between ischemic groups. No quantitation was
undertaken of clusterin or vimentin.capsule in most glomeruli.
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Fig. 1. Serum creatinines for all groups. (A )
Ischemic groups are: saline only (SI group;
h); SB 209670 (SBI group; ); and PD 156707
(PDI group; ). (B) Non-ischemic groups are:
(h) SI group; ( ) saline, no treatments (SC
group); ( ) SB 209670 (SBC group); and ( )
PD 156707 (PDC group). Ischemia refers to
the clamping of the renal pedicle at Day 0.
Intervention corresponds to infusion of either
ETR antagonist or saline. Where error bars
cannot be distinguished, the errors were too
small to be observed at this scale.
Collagen IV accumulation were observed in the amount of interstitial collagen III
between ischemic and nonischemic groups (P , 0.001;There was markedly less staining for collagen IV in
Fig. 7).the ischemic ETR antagonist groups (P , 0.001) when
compared with the SI group (Fig. 6). The SI group showed
Proliferating cellsthickening of Bowman’s capsules and selected tubular
Cells demonstrating staining for PCNA were mark-basement membranes as well as collagen IV staining
edly increased in those ischemic groups treated with ETRin the interstitium. There was difficulty in some areas
antagonists as compared with the SI ischemic group (P ,distinguishing between basement membranes and inter-
0.01; Fig. 8). There was no difference observed betweenstitium, as the integrity of tubular basement membranes
the SI group as compared with nonischemic controls.had been compromised. Nonischemic control groups
showed minimal staining for collagen IV when compared
TUNELwith their ischemic equivalents (P , 0.001; Fig. 6).
Apoptotic cells were evident throughout sections ob-
Collagen III accumulation tained from the SI ischemic group. The ischemic animals
treated with ETR antagonists had significantly fewerThere was no statistical difference between ischemic
groups when stained for collagen III (Fig. 7). Differences apoptotic cells (P , 0.005; Fig. 9). The nonischemic
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by serum creatinine, was not found after treatment with
either an ETA or ETA and ETB receptor antagonist. This
is probably a reflection of the relative insensitivity of
serum creatinine as a marker of renal failure [39–42].
Large variances in serum creatinine data may have also
reduced the probability of finding a difference that does
exist by reducing the experimental power (type II statisti-
cal error). These data, however, are consistent with the
data of Gellai et al [11, 12]. In their model of moderate
and severe IARF, plasma creatinines of rats treated with
BQ123 and SB 209670 were not significantly different
from untreated controls. Gellai et al demonstrated a
difference in the survival of rats with IARF treated with
ETR antagonists compared with those not treated. In ourFig. 2. Percent of the fractional area of the interstitium. Ischemic and
non-ischemic groups are compared. *P , 0.001 compared to the SI studies, there was no rat morbidity in any group, al-
ischemic group. No differences were found between nonischemic though the degree of renal impairment was the same forgroups.
the ischemic groups. One possible explanation may be
that our studies required less invasive instrumentation
of the rats while they were acutely unwell, when small
differences in potassium excretion may have been impor-group treated with PD 156707 showed an increase in
tant to survival.apoptosis as compared with its corresponding ischemic
a-Smooth muscle actin expression is a marker of myo-group PDI and the other non-ischemic groups SC and
fibroblast-like cells, a cell phenotype with features ofSBC (P , 0.05). This increase, however, was still signifi-
both fibroblasts and smooth muscle cells [43]. Myofi-cantly lower than that observed in the SI ischemic group
broblasts have been shown to be increased in many mod-(P , 0.002).
els of renal disease [18, 44–46]. Similarly, in this model
of IARF, a marked increase in myofibroblasts was found
DISCUSSION within the interstitium. There are no other reports of
An important role for ET in the pathogenesis of IARF myofibroblast proliferation as a response to IARF. Inter-
has been suggested. ET receptors are known to be up- stitial myofibroblasts are thought to be derived from a
regulated in models of ischemic ARF. Ischemic rat kid- resident cell population of the kidney [47], but whether
ney cortex expresses ETA and ETB receptors in a 50:50 this is from quiescent fibroblast/fibrocyte cells, the vascu-
ratio [32]. The glomerulus expresses mainly ETB recep- lature, or tubular epithelial transdifferentiation is un-
tors at high concentrations [33]. Increased ET-1 levels clear [48]. Grupp et al have shown transformation of
have been demonstrated in plasma [7], renal tissue [6], rat inner medullary fibroblasts to myofibroblasts in vitro
and cultured kidney cell lines [34] after periods of ische- when exposed to transforming growth factor-b (TGF-b),
mia. The kidney synthesizes all three isoforms of ET. PDGF, heparin, and extracellular matrix [49]. ET-1 may,
ET-1 is produced in the endothelial cells [35], mesangial therefore, contribute indirectly to myofibroblast recruit-
cells [36], and glomerular and tubular epithelial cells ment by stimulating monocytes and macrophages to pro-
[37]. Circulating cells can also produce ET-1, with macro- duce cytokines that may theoretically switch the resident
phages being an important source [38]. population of fibroblasts to myofibroblasts. In this study,
In this model of IARF, ETA and ETA/ETB receptor the accumulation of myofibroblasts was attenuated by
antagonists reduced the interstitial inflammatory infil- an infusion of the ETR antagonists, SB 209670 and PD
tration of Mo/Mφ and myofibroblasts. This was associ- 156707, 24-hours postischemia. It has been reported that
ated with changes in the extracellular matrix, marked ET-1 is a potent mitogen for rat fibroblasts and smooth
particularly by increased amounts of collagen type IV. muscle cells [50, 51]. A receptor antagonist would be
The number of proliferating cells was increased postis- expected to reduce proliferation of these cells if, as sug-
chemia in the ETR antagonist groups, whereas the pro- gested earlier here, ET was increased in IARF. Alterna-
portion of cells undergoing apoptosis was decreased. The tively, the response could be due to a reduction in other
control groups with no ischemic injury indicated that proliferative mediators/cytokines by ETR antagonists.
the changes were not due to compensatory hypertrophy Myofibroblasts also have a role in wound contraction
following nephrectomy nor due to the effects of the ETR [52], and Appleton et al reported that exposure to ET-
antagonists on the kidney undergoing compensatory hy- 1 caused a concentration-dependent contraction of gran-
pertrophy. ulation tissue [53].
The interstitium also contained Mo/Mφ. Although Mo/A significant change in renal function, as determined
Forbes et al: ETR antagonists in ischemic ARF in the rat204
Fig. 3. Photomicrograph (3100) at corticomedullary junction of a-smooth muscle actin staining in ischemic groups: (A) SI group (B) PDI group
(C) SBI group. Photomicrograph (3100) at corticomedullary junction of ED-1 staining for monocytes/macrophages: (D) SI group; (E) PDI group;
(F) SBI group. Publication of this figure in color was made possible by a grant from Pfizer, Ltd., Sandwich, Kent, UK.
Mφ express receptors for ET-1, there is no direct evi- therefore the monocyte infiltration [57]. ET-1 is also
produced by endothelial cells. This can be enhanced indence in the literature that ET-1 induces monocyte
chemoattraction or proliferation [54, 55]. Once again, vivo by Mφ secretion of IL-1 [58]. The observation that
infusion of SB 209670 or PD 156707 postischemia re-ET-1 may contribute indirectly by stimulating monocytes
to produce interleukin (IL)-1, TGF-b, IL-6, prostaglan- duces Mo/Mφ infiltration adds further weight to the
involvement of ET in fibrosis and regenerative tissuedin E2, granulocyte macrophage-colony stimulating fac-
tor (GM-CSF), and small amounts of tumor necrosis processes. The ability of these cells to produce TGF-b,
a profibrotic cytokine, may also complicate the inflam-factor [54]. A number of these substances are directly
or indirectly chemotactic for monocytes in vivo, espe- mation and interstitial damage.
As stated above, ET-1 is a potent mitogen for smoothcially IL-1 [56]. Macrophages in vitro have been shown
to produce ET-1, which may also act in an autocrine muscle cells. The effect of ET-1 on proliferation of other
cell types in the kidney is unknown. In previous studiesmanner to further amplify this cytokine response and
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Fig. 4. Morphometric quantitation of monocytes and macrophages.
Ischemic and non-ischemic groups, *P , 0.001 compared to the SI
Fig. 7. Morphometric quantitation of interstitial collagen III. Ischemicischemic group. No significant difference was found between the non-
groups, no difference was observed between SI, SBI and PDI. Non-ischemic groups.
ischemic groups, *P , 0.001 compared to SI group. No significant
difference was observed between non-ischemic groups.
Fig. 5. Morphometric quantitation of a-smooth muscle actin (a-SMA).
Ischemic and non-ischemic groups, *P , 0.001 compared to the SI Fig. 8. Morphometric quantitation of the percentage of proliferating
ischemic group. No significant difference was observed between nonis- cells with PCNA. Ischemic groups, *P , 0.01 compared to the SI
chemic groups. ischemic group. No significant difference was observed between SI and
nonischemic groups nor between individual non-ischemic groups.
of ARF, a rise in the number of macrophages in the
injured area preceded the acceleration of renal tubule
cell proliferation following injury [59]. In this model of
ischemic ARF, ETR antagonism increased the amount
of proliferating cells, particularly tubular epithelial cells.
This may be an indirect effect of receptor antagonism.
In the ischemic groups treated with SB 209670 and PD
156707, the numbers of macrophages and monocytes
have been significantly reduced. This may shorten the
duration of the postischemic inflammatory phase, and
the increased tubule proliferation may indicate recovery.
However, in the SI ischemic group, there is more histo-
logic evidence of inflammation marked by the greater
numbers of Mo/Mφ and myofibroblasts. The lack of pro-
Fig. 6. Morphometric quantitation of collagen IV. Ischemic and non-
liferation in this group suggests delayed tubule cell re-ischemic groups, *P , 0.001 compared to the SI ischemic group. No
significant difference was observed between the non-ischemic groups. generation in this setting.
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collagen IV was not the only component of the widened
interstitium. The increased deposition in this study may
be due to several factors, including de novo synthesis by
fibroblasts [18], increased tubule synthesis [14, 15, 62,
63], decreased collagenase production [64], and in-
creased synthesis of collagenase inhibitor by Mφ [62, 65,
66]. It was not possible under some circumstances to
distinguish between interstitial collagen IV and tubular
basement membrane collagen IV. This was especially
evident in the SI ischemic group.
It is tempting to speculate that the cellular changes
noted may be causally associated with the matrix changes.
Orphanides, Fine and Norman have shown increased
Fig. 9. Morphometric quantitation of the percentage of apoptotic cells amounts of collagen produced by cultured proximal tu-with TUNEL. Ischemic groups and non-ischemic groups, *P , 0.005
bule cells after exposure to hypoxia [64]. An effect ofcompared to the SI ischemic group. #P , 0.05, PDC nonischemic group
compared to the SC non-ischemic group. the ETR antagonists on the tubule cell production of
matrix may explain why the amount of collagen IV was
decreased but there was no change in the accumulation
of collagen III. There appeared to be a lack of protection
Schumer et al have shown that apoptosis is increased by the antagonists, however, from the accumulation of
after periods of renal ischemia [60]. The presence of collagen III. Although, statistically significant, this was
significantly more apoptotic cells in the SI ischemic group
only a 2% increase as compared with a 15% increase in
may be due to a more severe tubule cell injury, and may
collagen IV. This probably relates to the effects of ET
reflect the greater number of Mo/Mφ and myofibroblasts
on the different cell populations producing collagens IIIthat require removal from the kidney. Myofibroblasts
and IV.have been shown previously to be removed by apoptosis
In summary, our results indicate that the nonpeptidein some situations [46].
ETR antagonists PD 156707 (ETA) and SB 209670 (ETAQualitative staining for vimentin and clusterin was also
and ETB) decreased the cellular infiltration of Mo/Mφ,undertaken in this model. No differences were observed
the proliferation of myofibroblasts, and the accumulationbetween ischemic groups. Although these are markers
of collagen IV. The cell kinetics were also altered withof tubule injury, in the ischemic and nonischemic envi-
decreased apoptosis and increased proliferation ob-ronment vimentin expression was the same. Clusterin
served in the ischemic groups treated with ETR antago-appeared to be expressed in damaged tubular epithe-
nists. ET can be implicated as a mediator of the injurylium. No quantitation was undertaken of clusterin as
found in the postischemic kidney.there was granular staining of vesicle-like structures in
a number of tubule cells, making it difficult to distinguish
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creased in IARF. These changes were attenuated by
Abbreviations used in this article are: ABC, avidin-biotin-peroxi-
postischemic treatment with ETR antagonists. Increased dase complex; ARF, acute renal failure; a-SMA, a-smooth muscle
actin; dUTP, deoxyuridine triphosphate; ET, endothelin; ETR, ET re-deposition of collagen IV was evident in the interstitium,
ceptor; IARF, ischemic acute renal failure; IL, interleukin; PCNA,Bowman’s capsule, and the tubular basement mem-
proliferating cell nuclear antigen; TdT, terminal deoxynucleotidyl
branes. Although a large percentage of positive staining transferase; TGF-b, transforming growth factor-b; TUNEL, terminal
deoxytransferase uridine triphosphate nick end labeling.was observed in the interstitium, it should be noted that
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